Robert Holloway, MD
Gynecologic Oncology · Orlando, FLNPI 1538109137
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $284,848 of the $431,765 with a category attached, or 66.0%. 24 manufacturers reported payments, led by GSK at 36.3% of the total. Among gynecologic oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $1212.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$157K
- AstraZeneca$57K
- Merck$48K
- AbbVie$37K
- Davol Inc.$37K
- Eisai Inc.$36K
- plus $59K from 18 others
Across 469 payments — averaging $5711.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$617K
- Merck$528K
- F. Hoffmann-la Roche AG$413K
- Clovis Oncology, Inc.$346K
- Tesaro, Inc.$255K
- AbbVie$85K
- plus $435K from 12 others
What the payments were for
- Consulting fees$98,38023%
- Speaking & faculty fees$284,84866%
- Travel & lodging$36,9959%
- Food & beverage$11,1293%
- Education$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 90 | $156,883 |
| AstraZeneca | 36 | $56,905 |
| Merck | 33 | $48,081 |
| AbbVie | 25 | $37,351 |
| Davol Inc. | 18 | $37,303 |
| Eisai Inc. | 35 | $36,227 |
| Clovis Oncology, Inc. | 17 | $20,890 |
| Tesaro, Inc. | 19 | $19,132 |
| Biom'up SA | 12 | $12,269 |
| Daiichi Sankyo Inc. | 3 | $1,663 |
| Intuitive Surgical | 43 | $1,585 |
| Seagen Inc. | 1 | $1,575 |
| Biom'up France SAS | 10 | $723 |
| Johnson & Johnson | 2 | $202 |
| Aadi Bioscience, Inc. | 2 | $158 |
| Conmed Corporation | 2 | $152 |
| Bayer | 1 | $125 |
| Tempus AI, Inc | 1 | $100 |
| Myriad Genetic Laboratories, Inc. | 1 | $97 |
| Caris MPI, Inc. | 1 | $89 |
| BD | 1 | $78 |
| Genentech USA, Inc. | 1 | $64 |
| Integra Lifesciences Corporation | 1 | $58 |
| Genmab U.S., Inc. | 1 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$92,287
- JEMPERLI$80,318
- LYNPARZA$60,756
- Elahere$37,166
- KEYTRUDA$36,686
- LENVIMA$35,798
- Rubraca$20,615
- HEMOBLAST$12,135
- ARISTA AH$5,000
- PROGEL$4,206
- TIVDAK$1,575
- Enhertu$685
- Da Vinci Surgical System$425
- HemoBlast Bellows$332
- ARISTA AH FLEXITIP$138
- Vitrakvi$125
- VCARE$120
- AIRSEAL$120
- Echelon Powered Circular$116
How this compares
$431,765 in reported general payments places this provider in the 95th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 48 | $754,242 |
| LenvimaLenvatinib Mesylate | 18 | $385,731 |
| EliquisApixaban | 37 | $22,421 |
| Letrozole | 122 | $1,782 |
| Estradiol | 21 | $1,622 |
| Dexamethasone | 46 | $1,462 |
| Ondansetron Hcl | 90 | $1,368 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 53 | $683 |
| Prednisolone Acetate | 16 | $606 |
| Prochlorperazine Maleate | 67 | $593 |
| Gabapentin | 58 | $568 |
| Olanzapine | 132 | $378 |
| Ciprofloxacin Hcl | 27 | $142 |
| Metoclopramide Hcl | 140 | $120 |
| Prednisone | 25 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $56,905 | $754,24248 claims |
| Eisai Inc.Lenvima | $36,227 | $385,73118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 gynecologic oncology providers in Florida.
Other gynecologic oncology in Orlando
- Shelly SewardOrlando$349K
- Nathalie McKenzieOrlando$223K
- Jessica KennardOrlando$39K
- Christopher BryantOrlando$28K
- Veronica SchimpOrlando$5K
- James KendrickOrlando$3K
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
- Brian SlomovitzFort Lauderdale$519K
- Ricardo EstapeMiami$457K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.